Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: March 24, 2023

Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival lung patients. However, ICI leads to adaptive immune resistance and displays PD-1/PD-L1 blockade in cancer, leading less response Tumor microenvironment (TME) an integral tumor microenvironment, which involved immunotherapy resistance. Nanomedicine been used enhance cancer. In this review article, we described association between TME We also highlighted importance Moreover, discussed how nanoparticles are regulation improve efficacy immunotherapy, including SGT-53, AZD1080, Nanomodulator NRF2, Cisplatin nanoparticles, Au@PG, DPAICP@ME, SPIO NP@M-P, NBTXR3 ARAC Nano-DOX, MS NPs, Nab-paclitaxel, GNPs-hPD-L1 siRNA. Furthermore, concluded that targeting by could be helpful overcome

Language: Английский

---

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)

ESMO Open, Journal Year: 2023, Volume and Issue: 8(3), P. 101215 - 101215

Published: April 3, 2023

Language: Английский

---

SARS-CoV-2 infection as a potential risk factor for the development of cancer

Frontiers in Molecular Biosciences, Journal Year: 2023, Volume and Issue: 10

Published: Sept. 11, 2023

The COVID-19 pandemic has a significant impact on public health and the estimated number of excess deaths may be more than three times higher documented in official statistics. Numerous studies have shown an increased risk severe death patients with cancer. In addition, role SARS-CoV-2 as potential factor for development cancer been considered. Therefore, this review, we summarise available data effects infection oncogenesis, including but not limited to host signal transduction pathways, immune surveillance, chronic inflammation, oxidative stress, cell cycle dysregulation, viral genome integration, epigenetic alterations genetic mutations, oncolytic reactivation dormant cells. We also investigated long-term antiviral therapy used its progression.

Language: Английский

---

Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer

ESMO Real World Data and Digital Oncology, Journal Year: 2025, Volume and Issue: 8, P. 100125 - 100125

Published: March 14, 2025

Language: Английский

---

Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Oct. 4, 2023

The approval of immunotherapy (I-O) for the treatment late-stage non-small cell lung cancer (NSCLC) opened new perspectives in improving survival outcomes. However, data have not yet been provided from period Covid-19 pandemic. aims our study were to assess and compare outcomes patients with advanced LC receiving systemic anticancer (SACT) before after Hungary, examine impact pandemic on using Hungarian National Health Insurance Fund (NHIF) database.This retrospective, longitudinal included aged ≥20 years who diagnosed stage (LC) (ICD-10 C34) between 1 January 2011 31 December 2021 received SACT without LC-related surgery. Survival rates evaluated by year diagnosis, sex, age, histology.In total, 35,416 newly during (mean age at diagnosis: 62.1-66.3 years). In non-squamous carcinoma, 3-year was significantly higher among those 2019 vs. 2011-2012 (28.7% [95% CI: 26.4%-30.9%] 14.45% 13.21%-15.69%], respectively). squamous 22.3% (95% 19.4%-25.2%) 13.37% 11.8%-15.0%) 2011-2012, respectively, change statistically significant. Compared hazard ratio carcinoma 0.91, 0.82, 0.62 2015-2016, 2017-2018, 2019, respectively (p<0.001 all cases). group, corresponding ratios 0.93, 0.87, 0.78, improvements remained significant both patient populations (2020-2021). No found small carcinoma. Platinum-based chemotherapy most common first-line diagnostic periods, however, proportion first- or second-line increased period.3-year NSCLC almost doubled improved over past decade Hungary. Improvements could potentially be attributable introduction offset

Language: Английский

---

Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis

PLoS ONE, Journal Year: 2023, Volume and Issue: 18(9), P. e0291178 - e0291178

Published: Sept. 8, 2023

Background Lung cancer patients with coronavirus disease 2019 (COVID-19) infection experience high mortality rates. The study aims to determine the risk factors for in lung COVID-19 infection. Materials and methods Followed PRISMA reporting guidelines, PubMed, Embase, Web of Science were systematically searched February 20, 2023, studies main outcome interest was factor mortality. We also compared rate those among different continents. A pooled ratio (RR) 95% CI presented as result this meta-analysis. Results Meta-analysis 33 involving 5018 showed that 0.31 (95% CI: 0.25–0.36). Subgroup analysis based on continents significant difference observed between Asia rest world ( χ 2 = 98.96, P < 0.01). Older age (SMD: 0.24, 0.09–0.40, 0.01), advanced (RR: 1.14, 1.04–1.26, coexisting comorbidities such hypertension 1.17, 1.01–1.35, 0.04) cardiovascular 1.40, 1.03–1.91, 0.03) associated higher patients. Conclusions Findings meta-analysis confirms an increased infection, whose these appear be exacerbated by older age, advanced-stage cancer, disease.

Language: Английский

---

Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China

Journal of International Medical Research, Journal Year: 2024, Volume and Issue: 52(10)

Published: Oct. 1, 2024

Objective We examined the factors influencing hospitalization and prognosis among patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted therapy during first wave of coronavirus disease 2019 (COVID-19) pandemic. Methods In total, 267 diagnosed NSCLC who were treatment third-generation EGFR-TKIs included in our retrospective study. Data on patients’ demographics, clinical characteristics, survival collected analyzed. Results Over a mean follow-up 18 months, 80.5% (215/267) contracted COVID-19, 12.6% (27/215) these hospitalized for COVID-19 treatment. Vaccinated patients, those body mass index (BMI) ≥22.3 kg/m 2 , no comorbidities had lower rates infection than unvaccinated BMI <22.3 comorbidities, respectively. Continued was identified as risk patient survival. Conclusions can be continued received vaccines, higher BMI, without epidemic, but interruption might required active phase infection.

Language: Английский

---

Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: March 23, 2023

The corona virus disease 2019 (COVID-19) global pandemic has had an unprecedented and persistent impact on oncological practice, especially for patients with lung cancer, who are more vulnerable to the than normal population. Indeed, onset, progression, prognosis of two diseases may in some cases influence each other, inflammation is important link between them. original chronic inflammatory environment cancer increase risk infection COVID-19 exacerbate secondary damage. Meanwhile, acute caused by induce tumour progression or cause immune activation. In this article, from perspective microenvironment, pathophysiological changes lungs whole body these special will be summarised analysed explore possible immunological storm, immunosuppression, escape phenomenon complicated inflammation. effects cells, factors, chemokines, related target proteins microenvironment tumours also discussed, as well potential role vaccine checkpoint inhibitors setting. Finally, we provide recommendations treatment combined group.

Language: Английский

---

Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions

Cancers, Journal Year: 2024, Volume and Issue: 16(2), P. 304 - 304

Published: Jan. 11, 2024

: COVID-19 has been ravaging the globe for more than three years. Due to systemic immunosuppression of anti-tumor therapy, application chemotherapy and adverse effects surgery, short- long-term prognosis cancer patients are significant concern.

Language: Английский

---

Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1650 - 1650

Published: July 24, 2024

Cardiovascular disease and cancer are the two leading causes of morbidity mortality in world. The emerging field cardio-oncology described several shared risk factors that predispose patients to both cardiovascular cancer. Post-acute COVID-19 syndrome is a chronic condition occurs many who have experienced SARS-CoV-2 infection, mainly based on fatigue, sedentary lifestyle, cramps, breathing difficulties, reduced lung performance. exposes increased visceral adiposity, insulin resistance, myosteatosis, white adipose tissue content (surrounded by M1 macrophages characterized Th1/Th17 phenotype), which increases recurrence. In this review, main metabolic affections post-acute at low high cardiomyopathies will be summarized. Furthermore, non-pharmacological strategies aimed reducing atherosclerotic cardiac provided, especially through anti-inflammatory nutrition with glycemic index, appropriate physical activity, immune-modulating bioactivities able reduce obesity improving insulin-related signaling myocardial metabolism.

Language: Английский

---